Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment.
about
Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virusNew virologic tools for management of chronic hepatitis B and CUltrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome PredictorsAPASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat?Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies.Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.Real-Time PCR Assays for the Quantification of HCV RNA: Concordance, Discrepancies and Implications for Response Guided Therapy.A survey of hepatitis C treatment clinical practice patterns using the newly approved protease inhibitors.Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men.Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging.How to optimize HCV therapy in genotype 1 patients: predictors of response.HCV RNA viral load assessments in the era of direct-acting antivirals.NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety.Differences between quantification of genotype 3 hepatitis C virus RNA by Versions 1.0 and 2.0 of the COBAS AmpliPrep/COBAS TaqMan HCV Test.Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents.An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay.Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design.Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus - authors' reply.Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus.Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir.Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
P2860
Q26830190-664ACE21-2A5D-4C89-AF94-DC7DA2901EC1Q27026914-E34F340E-3908-452F-97EB-8608236E9435Q28553721-73EAF3D6-21C4-4441-B38C-4071F9AA2FBEQ30250088-CFA90080-52C6-4B28-B39A-E8C528ADD633Q34008754-05A79F7C-6503-4CB6-8656-8ED131EBEA14Q34485549-DABEFB3F-2B88-4F95-A5C0-3DF104B3FD0DQ35263756-5C598D85-EF6D-439C-8A16-8BF05CD1179DQ35412591-C2EB5812-63CF-40F8-90FB-6E7C988DAB85Q35746376-1D57BE58-F1A3-4051-A962-657436DDCA10Q37067537-33EF1FBB-5069-4531-A5A4-7D0023718F56Q37604517-44E4CBCC-1770-43BB-86AD-4B428290494EQ37682493-73C2A539-78C5-47C3-B310-C90E037D8285Q38071384-5F538C5B-8BC7-4831-8B73-38D06B6F3018Q38095710-D1194C1C-D339-47C1-B74E-45F30A683394Q38215505-89C0ACAF-11DA-4787-B587-88FA4FCA0D01Q38376757-3EC0E933-5648-4BE5-8AFC-1579435FF1A8Q39601072-F72A8FF1-84D8-46F3-8169-97BEDD98A9EAQ41476752-2519C3E7-C012-4388-9516-3B6B7A4D65CEQ41913531-6C2AE9A6-1854-40FD-9A34-94D4FA3F6AF9Q42239220-C5C58E49-7F12-4827-AB92-381F29160A09Q42239228-1F4F1FAF-F4BB-41D4-BE5E-101146BA79DEQ42256950-582FEB47-C6D2-47A9-8574-B3597EF6D039Q42980599-D4AEB47C-76B4-4A9A-8933-AA505C2BD9FE
P2860
Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Clinical relevance of detectab ...... revir or telaprevir treatment.
@en
Clinical relevance of detectab ...... revir or telaprevir treatment.
@nl
type
label
Clinical relevance of detectab ...... revir or telaprevir treatment.
@en
Clinical relevance of detectab ...... revir or telaprevir treatment.
@nl
prefLabel
Clinical relevance of detectab ...... revir or telaprevir treatment.
@en
Clinical relevance of detectab ...... revir or telaprevir treatment.
@nl
P2093
P2860
P356
P1433
P1476
Clinical relevance of detectab ...... revir or telaprevir treatment.
@en
P2093
Lisa K Naeger
Patrick R Harrington
P2860
P304
P356
10.1002/HEP.24791
P407
P577
2012-03-01T00:00:00Z